Nuceiva (botulinum toxin type a)
Additional monitoring
- Region
- 🇪🇺 EU
- Active substance
- botulinum toxin type a
- Company
- Evolus Pharma B.V.
- Status
- Authorised
- Therapeutic area
- Skin Aging
- EU approval
- Fri 27 Sep 2019
- Designations
- Additional monitoring
- Application
- EMEA/H/C/004587
- ATC
- M03AX01
- Official record
- www.ema.europa.eu
Indication
Temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows seen at maximum frown (glabellar lines), when the severity of the above facial lines has an important psychological impact in adults below 65 years of age.
Regulatory milestones
No milestones recorded in the last year.
Follow Nuceiva
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.